- Home
- EPIX vs GNLX Comparison
EPIX vs GNLX Comparison
Compare EPIX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- GNLX
- Stock Information
- Founded
- EPIX 2009
- GNLX 2001
- Country
- EPIX Canada
- GNLX United States
- Employees
- EPIX N/A
- GNLX N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- GNLX Health Care
- Exchange
- EPIX Nasdaq
- GNLX Nasdaq
- Market Cap
- EPIX 77.2M
- GNLX 81.5M
- IPO Year
- EPIX N/A
- GNLX 2023
- Fundamental
- Price
- EPIX $1.75
- GNLX $2.46
- Analyst Decision
- EPIX Hold
- GNLX Strong Buy
- Analyst Count
- EPIX 3
- GNLX 4
- Target Price
- EPIX $2.00
- GNLX $18.25
- AVG Volume (30 Days)
- EPIX 425.3K
- GNLX 80.9K
- Earning Date
- EPIX 02-11-2025
- GNLX 11-14-2024
- Dividend Yield
- EPIX N/A
- GNLX N/A
- EPS Growth
- EPIX N/A
- GNLX N/A
- EPS
- EPIX N/A
- GNLX N/A
- Revenue
- EPIX N/A
- GNLX $8,000.00
- Revenue This Year
- EPIX N/A
- GNLX N/A
- Revenue Next Year
- EPIX N/A
- GNLX N/A
- P/E Ratio
- EPIX N/A
- GNLX N/A
- Revenue Growth
- EPIX N/A
- GNLX N/A
- 52 Week Low
- EPIX $1.40
- GNLX $1.60
- 52 Week High
- EPIX $11.67
- GNLX $12.59
- Technical
- Relative Strength Index (RSI)
- EPIX 41.97
- GNLX 48.80
- Support Level
- EPIX $1.70
- GNLX $2.25
- Resistance Level
- EPIX $1.85
- GNLX $2.57
- Average True Range (ATR)
- EPIX 0.10
- GNLX 0.19
- MACD
- EPIX 0.03
- GNLX 0.01
- Stochastic Oscillator
- EPIX 43.66
- GNLX 41.18
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.